Apixaban for the Acute Treatment of Venous Thromboembolism in Children

NCT ID: NCT02464969

Last Updated: 2024-10-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

229 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-22

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Apixaban

Subjects between birth to \<18 years will be dosed on a body weight tiered regimen. Subjects ≥35kg will receive 10mg twice daily(BID) for 7 days followed by 5mg BID thereafter;\<35kg to 25kg will receive 8mg BID for 7 days followed by 4mg BID thereafter;\<25 to 18kg will receive 6mg BID for 7 days and then 3mg BID thereafter;\<18 to 12kg will receive 4mg BID for 7 days and then 2mg BID thereafter;\<12 to 9kg will receive 3mg BID for 7 days and then 1.5mg BID thereafter;\< 9kg to 6kg will receive 2 mg BID for 7 days and 1mg BID thereafter;\<6kg to 5kg will receive 1mg BID for 7 days and 0.5mg BID thereafter;\<5kg to 4kg will receive 0.6mg twice daily for 7 days and 0.3mg BID thereafter;PK cohort neonates ≥ 2.6kg will receive 0.1mg BID. Dose will be adjusted as determined by PK measurements (ie, to 0.2mg BID, 0.1mg daily or dose will stay the same).For the post PK cohort Neonates ˂4kg to 2.6kg, if confirmed by PK sub analysis,subjects will receive 0.2mg BID for 7 days and 0.1mg BID thereafter.

Group Type EXPERIMENTAL

Apixaban

Intervention Type DRUG

Tablet or Solution

Standard of Care

Intervention Type DRUG

Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apixaban

Tablet or Solution

Intervention Type DRUG

Standard of Care

Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Birth to \<18 years of age with a minimum weight of 2.6 kg at the time of randomization.
2. Presence of an index VTE which is confirmed by imaging.
3. Intention to manage the index VTE with anticoagulation treatment for at least 6 to 12 weeks.
4. Subjects able to tolerate oral feeding, nasogastric (NG), gastric (G) feeding and are currently tolerating enteric medications, as per investigator's judgement.

Exclusion Criteria

1. Anticoagulant treatment for the index VTE for greater than 14 days prior to randomization. Neonates that are enrolled into the PK cohort must be on a minimum of 5 days and a maximum of 14 days SOC anticoagulation prior to randomization. Neonates that are enrolled into the post PK cohort may receive SOC anticoagulation for up to 14 days prior to randomization.
2. Thrombectomy, thrombolytic therapy, or insertion of a caval filter to treat the index VTE.
3. A mechanical heart valve.
4. Active bleeding or high risk of bleeding at the time of randomization.
5. Intracranial bleed, including intraventricular hemorrhage, within 3 months prior to randomization.
6. Abnormal baseline liver function at randomization.
7. Inadequate renal function at the time of randomization.
8. Platelet count \<50×109 per L at randomization.
9. Uncontrolled severe hypertension at the time of randomization.
10. Use of prohibited concomitant medication at the time of randomization.
11. Female subjects who are either pregnant or breastfeeding a child.
12. Use of aggressive life-saving therapies such as ventricular assist devices (VAD) or extracorporeal membrane oxygenation (ECMO) at the time of enrollment.
13. Unable to take oral or enteric medication via the NG or G tube.
14. Known inherited or acquired antiphospholipid syndrome (APS).
15. Known inherited bleeding disorder or coagulopathy with increased bleeding risk (eg, hemophilia, von Willebrand disease, etc.)
Minimum Eligible Age

0 Days

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role collaborator

Bristol-Myers Squibb

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Loma Linda University Cancer Center

Loma Linda, California, United States

Site Status

Loma Linda University Children's Hospital

Loma Linda, California, United States

Site Status

Loma Linda University Medical Center

Loma Linda, California, United States

Site Status

Pediatric Cardiology Clinic

Birmingham, Alabama, United States

Site Status

University of Alabama

Birmingham, Alabama, United States

Site Status

Phoenix Children's Hospital

Phoenix, Arizona, United States

Site Status

Valley Children's Hospital

Madera, California, United States

Site Status

Children's Hospital and Research Center Oakland

Oakland, California, United States

Site Status

Bass Speicalty Pharmacy

Palo Alto, California, United States

Site Status

Inpatient Pharmacy

Palo Alto, California, United States

Site Status

Lucile Packard Children's Hosptial - Stanford University

Palo Alto, California, United States

Site Status

University of California Davis Comprehensive Cancer Center

Sacramento, California, United States

Site Status

Loma Linda University Health Care

San Bernardino, California, United States

Site Status

UCSF Benioff Children's Hospital

San Francisco, California, United States

Site Status

UCSF Mission Bay Pediatric Clinical Research Center

San Francisco, California, United States

Site Status

Children's Hospital Colorado - Investigational Drug Services

Aurora, Colorado, United States

Site Status

Children's Hospital Colorado

Aurora, Colorado, United States

Site Status

Connecticut Children's Medical Center Pharmacy

Hartford, Connecticut, United States

Site Status

Connecticut Children's Medical Center

Hartford, Connecticut, United States

Site Status

Nemours/ Alfred I. duPont Hospital for Children

Wilmington, Delaware, United States

Site Status

Childrens National Medical Center

Washington D.C., District of Columbia, United States

Site Status

UF Health Shands Hospital

Gainesville, Florida, United States

Site Status

JDCH Division of Pediatric Hematology and Oncology

Hollywood, Florida, United States

Site Status

Joe DiMaggio Children's Hospital

Hollywood, Florida, United States

Site Status

Memorial Regional Hospital

Hollywood, Florida, United States

Site Status

Nicklaus Children's Hospital

Miami, Florida, United States

Site Status

AdventHealth Orlando

Orlando, Florida, United States

Site Status

AdventHealth Orlando-Pharmacy Investigational Drug Services

Orlando, Florida, United States

Site Status

AdventHealth Pediatric Oncology Hematology at Orlando

Orlando, Florida, United States

Site Status

St. Joseph's Hospital

Tampa, Florida, United States

Site Status

Children's Hematology and Oncology a division of Kidz medical Service

West Palm Beach, Florida, United States

Site Status

St. Mary's Medical Center

West Palm Beach, Florida, United States

Site Status

Children's Healthcare of Atlanta-Egleston

Atlanta, Georgia, United States

Site Status

Children's Healthcare of Atlanta Center for Advanced Pediatrics - Pediatric Research Unit

Atlanta, Georgia, United States

Site Status

Children's Healthcare of Atlanta Center for Advanced Pediatrics-IDS Pharmacy

Atlanta, Georgia, United States

Site Status

Ann & Robert H Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Site Status

Bleeding and Clotting Disorders Institute

Peoria, Illinois, United States

Site Status

Unity Point Methodist Medical Center

Peoria, Illinois, United States

Site Status

OSF Saint Francis Medical Center

Peoria, Illinois, United States

Site Status

Indiana University

Indianapolis, Indiana, United States

Site Status

IU Health Pharmacy

Indianapolis, Indiana, United States

Site Status

Riley Hospital for Children at IU Health

Indianapolis, Indiana, United States

Site Status

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status

University of Kentucky Medical Center

Lexington, Kentucky, United States

Site Status

Boston Children's Hospital

Boston, Massachusetts, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Children's Hospital of Michigan

Detroit, Michigan, United States

Site Status

University of Mississippi Medical Center

Jackson, Mississippi, United States

Site Status

Children's Mercy Hospital

Kansas City, Missouri, United States

Site Status

Hackensack University Medical Center

Hackensack, New Jersey, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

New York-Presbyterian Morgan Stanley Children's Hospital

New York, New York, United States

Site Status

SUNY Upstate Medical University

Syracuse, New York, United States

Site Status

Levine Children's Specialty Center

Charlotte, North Carolina, United States

Site Status

Levine Children's Hospital, Pediatric Research

Charlotte, North Carolina, United States

Site Status

Levine Children's Hospital

Charlotte, North Carolina, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Investigational Drug Service, Duke University Hospital

Durham, North Carolina, United States

Site Status

Sanford Children's Hospital

Fargo, North Dakota, United States

Site Status

Sanford Roger Maris Cancer Center

Fargo, North Dakota, United States

Site Status

Akron Children's Hospital

Akron, Ohio, United States

Site Status

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Site Status

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

Nationwide Children's Hospital

Columbus, Ohio, United States

Site Status

OU Medical Center Investigational Drug Pharmacy

Oklahoma City, Oklahoma, United States

Site Status

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

Site Status

The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

St. Christopher's Hospital for Children

Philadelphia, Pennsylvania, United States

Site Status

UPMC Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

Medical University of South Carolina: Investigational Drug Services

Charleston, South Carolina, United States

Site Status

Medical University of South Carolina: Shawn Jenkins Women's and Children's Hospital

Charleston, South Carolina, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Monroe Carell Jr. Children's Hospital at Vanderbilt

Nashville, Tennessee, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Texas Children's Hospital- Main Hospital

Houston, Texas, United States

Site Status

Texas Children's Hospital- Wallace Tower

Houston, Texas, United States

Site Status

The Children's Hospital of San Antonio

San Antonio, Texas, United States

Site Status

University of Texas Health San Antonio

San Antonio, Texas, United States

Site Status

Primary Children's Hospital

Salt Lake City, Utah, United States

Site Status

Seattle Children's Hospital

Seattle, Washington, United States

Site Status

Children's Hospital of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

Versiti Wisconsin

Milwaukee, Wisconsin, United States

Site Status

Kids Cancer Centre

Randwick, New South Wales, Australia

Site Status

Prince of Wales Hospital

Sydney, New South Wales, Australia

Site Status

The Royal Childrens Hospital

Parkville, VC, Australia

Site Status

A.o.Landeskrankenhaus Innsbruck

Innsbruck, Tyrol, Austria

Site Status

Medizinische Universitaet Innsbruck

Innsbruck, , Austria

Site Status

Medizinische Universitaet Wien

Vienna, , Austria

Site Status

Kaye Edmonton Clinic

Edmonton, Alberta, Canada

Site Status

Stollery Children's Hospital

Edmonton, Alberta, Canada

Site Status

Hamilton Health Science Corporation/McMaster Children's Hospital

Hamilton, Ontario, Canada

Site Status

The Hospital For Sick Children

Toronto, Ontario, Canada

Site Status

CHU Sainte-Justine

Montreal, Quebec, Canada

Site Status

Hopital de la Timone Enfants

Marseille, , France

Site Status

CHRU de Montpellier - Hopital Arnaud de Villeneuve

Montpellier, , France

Site Status

Hopital Necker-Enfants malades

Paris, , France

Site Status

CHU de Bordeaux - Hopital Haut-Leveque

Pessac, , France

Site Status

Service d'Imagerie Medicale du Pr F. Laurent

Pessac, , France

Site Status

Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK)

Berlin, , Germany

Site Status

Universitätsklinikum Essen

Essen, , Germany

Site Status

Technische Universitat, Deutsches Herzzentrum Munchen

München, , Germany

Site Status

Hadassah Medical Center (Ein Kerem)

Jerusalem, , Israel

Site Status

O.P.D Hospital Civil de Guadalajara, Hospital Civil Fray Antonio Alcalde

Guadalajara, Jalisco, Mexico

Site Status

Instituto Nacional De Cardiologia Ignacio Chavez

Mexico City, , Mexico

Site Status

State Autonomous Healthcare Institution "Children's Republican Clinical Hospital of Ministry of

Kazan', Republic Tatarstan, Russia

Site Status

State Autonomous Healthcare Institution of Sverdlovsk Region

Yekaterinburg, Sverdlovsk Oblast, Russia

Site Status

FSBI "NRMC PHOI n.a.Dmitry Rogachev" of Minzdrav Russia

Moscow, , Russia

Site Status

Hospital Sant Joan de Deu

Esplugues de Llobregat, Barcelona, Spain

Site Status

Hospital Universitario HM Monteprincipe

Boadilla del Monte, Madrid, Spain

Site Status

Hospital Universitario Vall d´Hebron

Barcelona, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Adana Acibadem Hospital

Seyhan, Adana, Turkey (Türkiye)

Site Status

Baskent Universitesi Tip Fakultesi Cocuk Sagligi ve Hastaliklari ABD Cocuk Hematoloji Onkoloji BD

Bahçelievler, Ankara, Turkey (Türkiye)

Site Status

Hacettepe University Faculty of Medicine, Ihsan Dogramaci Children's Hospital

Ankara, , Turkey (Türkiye)

Site Status

Ankara City Hospital Pediatric Hematology and Oncology Clinic

Ankara, , Turkey (Türkiye)

Site Status

Ege Universitesi Tip Fakultesi Cocuk Hastanesi Cocuk Hematoloji Bilim Dali

Izmir, , Turkey (Türkiye)

Site Status

Communal Enterprise "Dnipropetrovsk Specialized Clinical Medical Center of Mother and Child

Dnipro, , Ukraine

Site Status

Dnipropetrovsk Regional Children's Hospital

Dnipro, , Ukraine

Site Status

Municipal enterprise "Dnipropetrovsk Regional Children's Clinical Hospital"

Dnipro, , Ukraine

Site Status

Communal Institution "Zaporizhzhia Regional Clinical Children's Hospital"

Zaporizhzhia, , Ukraine

Site Status

Royal Hospital for Children

Glasgow, Scotland, United Kingdom

Site Status

Newcastle Upon Tyne Hospitals NHS Foundation Trust

Newcastle upon Tyne, TYNE & WEAR, United Kingdom

Site Status

Cardiff & Vale NHS Health Board

Cardiff, Wales, United Kingdom

Site Status

Noah's Ark Children's Hospital for Wales

Cardiff, Wales, United Kingdom

Site Status

Birmingham Children's Hospital NHS Foundation Trust

Birmingham, WEST Midlands, United Kingdom

Site Status

Birmingham Women's and Children's NHS Foundation Trust

Birmingham, WEST Midlands, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Canada France Germany Israel Mexico Russia Spain Turkey (Türkiye) Ukraine United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://pmiform.com/clinical-trial-info-request?StudyID=B0661037

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-002606-20

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CV185-325

Identifier Type: OTHER

Identifier Source: secondary_id

B0661037

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Calf Deep Vein Thrombosis Treatment Trial
NCT03590743 TERMINATED PHASE4